Athira Pharma (NASDAQ:LONA) Upgraded at Citizens Jmp

Citizens Jmp upgraded shares of Athira Pharma (NASDAQ:LONA) from a market perform rating to an outperform rating in a research report sent to investors on Thursday morning, Marketbeat.com reports. Citizens Jmp currently has $18.00 price objective on the stock.

Other analysts also recently issued research reports about the stock. Piper Sandler assumed coverage on shares of Athira Pharma in a research report on Wednesday, May 27th. They set an “overweight” rating and a $20.00 price objective for the company. Wall Street Zen raised shares of Athira Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Athira Pharma in a research note on Monday, May 11th. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $16.00.

Athira Pharma Stock Down 3.2%

LONA stock opened at $7.06 on Thursday. The business has a 50 day moving average price of $8.46 and a 200 day moving average price of $8.05. The stock has a market cap of $66.29 million, a price-to-earnings ratio of -1.36 and a beta of 2.01. Athira Pharma has a fifty-two week low of $3.24 and a fifty-two week high of $14.21.

Athira Pharma (NASDAQ:LONA) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($1.73) earnings per share (EPS) for the quarter. As a group, sell-side analysts anticipate that Athira Pharma will post -3.12 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Commodore Capital LP purchased a new stake in Athira Pharma in the fourth quarter valued at approximately $3,515,000. Seven Fleet Capital Management LP purchased a new position in shares of Athira Pharma during the fourth quarter worth approximately $969,000. Spruce Street Capital LP purchased a new position in shares of Athira Pharma during the fourth quarter worth approximately $2,980,000. Millennium Management LLC acquired a new position in shares of Athira Pharma in the 4th quarter valued at $2,456,000. Finally, ADAR1 Capital Management LLC acquired a new position in shares of Athira Pharma in the 4th quarter valued at $2,891,000. Institutional investors and hedge funds own 57.12% of the company’s stock.

Athira Pharma Company Profile

Athira Pharma, Inc is a clinical‐stage biopharmaceutical company headquartered in Seattle, Washington, that is dedicated to developing therapies aimed at restoring neuronal health and slowing the progression of neurodegenerative diseases. Founded in 2011, Athira’s research focuses on the Hepatocyte Growth Factor (HGF)/MET pathway as a novel mechanism to promote neuronal repair, synaptic function and overall cognitive performance. The company’s overarching goal is to offer disease‐modifying treatments for conditions such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and amyotrophic lateral sclerosis (ALS).

The centerpiece of Athira’s pipeline is fosgonimeton (ATH‐1017), a small‐molecule positive modulator of the HGF/MET system.